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ABSTRACT
Background. Recurrence of intrahepatic cholangiocarci-
noma (ICC) after curative resection is common.
Objective. The aim of this study was to investigate the
patterns, timing and risk factors of disease recurrence after
curative-intent resection for ICC.
Methods. Patients undergoing curative resection for ICC
were identified from a multi-institutional database. Data on
clinicopathological and initial operation information,
timing and first sites of recurrence, recurrence manage-
ment, and long-term outcomes were analyzed.
Results. A total of 920 patients were included. With a
median follow-up of 38 months, 607 patients (66.0%)
experienced ICC recurrence. In the cohort, 145 patients
(23.9%) recurred at the surgical margin, 178 (29.3%)
recurred within the liver away from the surgical margin, 90
(14.8%) recurred at extraheptatic sites, and 194 (32.0%)
developed both intrahepatic and extrahepatic recurrence.
Intrahepatic margin recurrence (median 6.0 m) and extra-
hepatic-only recurrence (median 8.0 m) tended to occur
early, while intrahepatic recurrence at non-margin sites
occurred later (median 14.0 m; p\ 0.05). On multivariate
analysis, surgical margin\ 10 mm was associated with
increased margin recurrence (hazard ratio [HR] 1.70, 95%
confidence interval [CI] 1.11–2.60; p = 0.014), whereas
female sex (HR 2.12, 95% CI 1.40–3.22; p\ 0.001) and
liver cirrhosis (HR 2.36, 95% CI 1.31–4.25; p = 0.004)
were both associated with an increased risk of intrahepatic
recurrence at other sites. Median survival after recurrence
was better among patients who underwent repeat curative-
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intent surgery (48.7 months) versus other treatments
(9.7 months) [p\ 0.001].
Conclusions. Different recurrence patterns and timing of
recurrence suggest biological heterogeneity of ICC tumor
recurrence. Understanding timing and risk factors associ-
ated with different types of recurrence can hopefully
inform discussions around adjuvant therapy, surveillance,
and treatment of recurrent disease.
Surgical resection is the best potentially curative treat-
ment option for patients with intrahepatic
cholangiocarcinoma (ICC).1 However, long-term prognosis
after curative resection remains dismal, with a 5-year sur-
vival rate of 20–35%.2,3 The main reason for an
unfavorable long-term outcome after resection of ICC is
the high incidence of tumor recurrence, which ranges from
50 to 70%.2,4,5. While recurrence is common, the biological
behavior of ICC tumors can vary.2,4,5 Of note, the differ-
ence in disease biology and progression, as well as timing
and patterns of recurrence, cannot be fully explained or
predicted by tumor stage.6,7
Management of recurrent ICC can be clinically chal-
lenging. While there are scant data in the literature that
define treatment of recurrent disease, several investigators
have examined the benefits of re-treatment of recurrence.
In particular, several groups have reported on varied ther-
apeutic procedures to treat different types of recurrence,
including intrahepatic-only, extrahepatic-only and both
intrahepatic and extrahepatic recurrent disease.4,8 Similar
to hepatocellular carcinoma (HCC), ICC most frequently
recurs within the liver itself.4,9,10 Varying locations of
intrahepatic recurrence (e.g. de novo intrahepatic site vs.
margin recurrence) might imply different tumor biology
and subsequently different disease treatment and postop-
erative prognosis. Our group and others have previously
reported on the time course of any site recurrence after
surgery for primary liver cancers, including HCC and
ICC.3,9,11 Based on data from these previous studies, a
2-year cut-off value has been utilized as the optimal means
to differentiate early versus late recurrence.11 Interestingly,
early recurrence has been associated with tumor charac-
teristics and technical factors, while late recurrence has
been associated with underlying liver disease.4,12–16 These
data serve to emphasize how a more accurate and detailed
understanding of the time course associated with different
recurrence patterns, as well as the factors predicting
specific recurrence patterns, after resection for ICC may be
important. Characterizing recurrence following curative
intent surgery for ICC can better delineate the risk of
recurrence and therefore help tailor postoperative moni-
toring and perioperative adjuvant treatment strategies.
Given the paucity of data available on recurrence following
ICC, and in particular the treatment of different site
recurrences, the objective of the current study was to
characterize patterns and timing of disease recurrence
following resection of ICC using a large, multi-institu-
tional, international database. In addition, we sought to
define specific outcomes among patients with different
patterns of recurrent ICC.
PATIENTS AND METHODS
Patients undergoing curative-intent resection for ICC
between April 1990 and August 2017 were identified from
a multi-institutional database from 15 hepatobiliary centers
in North America, Europe, Australia and Asia. Only
patients who underwent curative-intent resection for his-
tologically confirmed ICC were included. Resection with
curative intent was defined as macroscopic removal of all
tumors (R0 or R1 resection). Patients undergoing palliative
(R2) resection, ablation only, intra-arterial therapy only or
with extrahepatic metastasis were excluded. The Institu-
tional Review Boards of each participating institution
approved the study.
Data Collection and Follow-Up
A standardized datasheet was created for collection of
the clinicopathological, and surgical information. Patho-
logic staging was recoded according to the 8th edition
American Joint Committee on Cancer (AJCC) staging
guidelines for all study subjects.17 Resection margin status
was defined as R0 when the tumor margin was micro-
scopically negative, and R1 when the tumor margin was
microscopically positive. Satellite lesions were defined as
tumors surrounding the main tumor with multiple other
satellite nodules or small solitary tumors located near the
main tumor that were histologically similar or less differ-
entiated than the main tumor.18
After surgery, patients were regularly followed once
every 3–4 months within the first 3 years and then once
every 6 months until year 5, after which screening occurred
annually. Patients were prospectively monitored for
recurrence with serum tumor markers and imaging studies,
including ultrasonography, computed tomography (CT)
and/or magnetic resonance imaging (MRI). Recurrence
was defined as a biopsy-proven recurrent lesion or radio-
logical evidence with cross-sectional imaging plus an
elevated cancer antigen (CA) 19-9 level. Disease-free
survival (DFS) was defined as the time duration from the
date of initial surgery to tumor recurrence, while overall
survival (OS) after recurrence was defined as the time
duration from the date of recurrence after surgery to patient
death or the end of the study, whichever came first.
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Tumor recurrence sites were classified as intrahepatic
recurrence at the surgical margin, intrahepatic recurrence
other than surgical margin, extrahepatic recurrence only,
and intrahepatic plus extrahepatic recurrence based on CT,
MRI and/or positron emission tomography (PET)-CT. The
initial recurrence site that was identified was utilized for
purposes of analysis. Recurrence at the intrahepatic margin
was defined as recurrence in the surgical bed or the same
segment(s) as the original tumor, whereas intrahepatic
recurrence at an ‘other’ site was defined as recurrent dis-
ease in an area other than the operative segment(s).
Curative surgical intent therapy for recurrence was defined
as macroscopic removal of all recurrent tumors with re-
resection, ablation, or combined resection plus ablation.
Non-curative surgical intent therapy for recurrence was
defined as ablation for patients with multiple nodules or
resection of liver disease in the setting of extrahepatic
disease.
Statistical Analysis
Continuous variables were expressed as medians with
interquartile ranges (IQRs) and were compared using the
Student t test or Mann–Whitney U test. Statistical com-
parisons for categorical variables were made using the Chi-
square test or Fisher’s exact test. Kaplan–Meier curves
were used to estimate median DFS and OS after recurrence,
with corresponding 95% confidence intervals (CIs); the
log-rank test was performed for pairwise comparison of
recurrence patterns. Factors associated with DFS among
patients with different recurrence patterns were identified
using univariate and multivariate Cox proportional hazards
regression models. Hazard ratios (HRs) and 95% CIs were
estimated. Variables with a p value\ 0.05 on univariate
analysis were included in the multivariate models. A two-
tailed p value\ 0.05 was considered statistically signifi-
cant. Statistical analyses were performed using SPSS
version 21.0 (IBM SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 920 patients who underwent curative-intent
resection for ICC were included in the analytic cohort
(Table 1). Median patient age was 59 years (IQR 51–68)
and more than half of the patients were male (n = 517,
56.2%). Among all patients, 116 (12.6%) patients pre-
sented with liver cirrhosis. Median tumor size was 6 cm
(IQR 4.1–8.5) and 162 (17.6%) patients had two or more
lesions; 169 (18.4%) patients underwent an R1 resec-
tion. Less than half of patients (407/920, 44.2%) underwent
a concomitant lymphadenectomy. Among the 407 patients
who had a nodal dissection, 171 (42.0%) patients had at
least one lymph node metastasis.
Recurrence Patterns and Disease-Free Survival
With a median follow-up of 38 months, 607 (66.0%)
patients experienced tumor recurrence following resection,
while 313 (34.0%) patients had no evidence of recurrence
at the time of last follow-up. Among the entire analytic
cohort, 380 (41.3%) patients died of tumor recurrence,
while 57 (6.2%) patients died of other causes; 227 (24.7%)
patients were alive with recurrent disease, while 256
(27.8%) were alive free of tumor recurrence. Median, 1-,
3-, and 5-year DFS for the entire cohort was 17.1 months
(95% CI 14.2–19.7), 57.5, 34.5, and 29.5%, respectively,
while median, 1-, 3-, and 5-year OS was 38.6 months (95%
CI 33.9–44.1), 81.3, 51.5, and 25.5%, respectively.
Among the 607 patients who recurred, 323 (53.2%)
patients experienced intrahepatic-only recurrence. Among
these patients, 145 (23.9%) recurred at the surgical margin,
while 178 (29.3%) recurred at a different site within the
liver. In contrast, 90 (14.8%) patients had extrahepatic-only
recurrence and 194 (32.0%) patients developed both
intrahepatic and extrahepatic recurrence. Extrahepatic
recurrent disease was noted most often in the lungs
(n = 55); other extrahepatic recurrent sites included lymph
nodes (n = 46), peritoneum (n = 34), bone (n = 13), and
adrenal (n = 5). Among the 194 patients who had intra-
hepatic and extrahepatic recurrence, 134 (69.1%) patients
had intrahepatic disease at a location away from the initial
surgical margin, while 60 (30.9%) patients had intrahepatic
lesion at or near the previous surgical margin.
Among the 607 patients who recurred, 374 (61.6%) had
tumor recurrence within 12 months, and 506 (83.3%)
patients had tumor recurrence within 24 months after sur-
gery. Of note, recurrence location differed according to the
time of recurrence (Fig. 1a). Within the initial 6 months
following surgery, intrahepatic margin recurrence (n = 73,
37.8%) and concomitant intrahepatic plus extrahepatic
recurrence (n = 63, 32.6%) were the two most common
recurrence patterns. While the incidence of intrahepatic
margin recurrence decreased over time following the first
6 months after surgery, intrahepatic recurrence at other
sites gradually increased in the postoperative period
(13.0% in 1–6 months vs. 35.4% in 6–12 months vs. 41.7%
in 12–24 months; p\ 0.001 for trend). Approximately
one-half (n = 73, 50.3%) of patients who recurred at or
near the surgical margin recurred within 6 months after
surgery (Fig. 1b). In contrast, most patients who developed
an intrahepatic recurrence at a non-surgical site, as well as
patients who had extrahepatic-only or intrahepatic plus
extrahepatic recurrence recurred within 12 months after
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surgery. Of note, the ratio of extrahepatic-only recurrence
(14.8%) versus intrahepatic plus extrahepatic recurrence
(32.0%) remained relatively constant following surgery
(p = 0.59).
Of note, a small subset of patients (n = 22, 3.6%)
developed a recurrence more than 5 years after surgery.
Among these 22 patients, intrahepatic recurrence at the
resection bed was noted in five patients, while intrahepatic
TABLE 1 Clinical and pathological characteristics of patients
Variable Whole cohort (n = 920) With recurrence (n = 607) Without recurrence (n = 313) p value
Age, years [median (IQR)] 59 (51–68) 59 (49–67) 60 (52–68) 0.072
Men 517 (56.2) 343 (56.5) 174 (55.6) 0.770
BMI (kg/m2) 25.1 (22.2–27.8) 25.3 (22.3–28.2) 24.2 (21.8–26.7) 0.003
Liver cirrhosis 116 (12.6) 75 (12.4) 41 (13.1) 0.839
CA19-9 (units/ml) 55.0 (17.0–308.1) 77.0 (18.8–456.0) 51.5 (16.5–243.8) \ 0.001
CEA (ng/ml) 2.4 (1.3–4.2) 2.4 (1.3–4.3) 2.4 (1.5–4.0) 0.418
Tumor size, cm [median (IQR)] 6.0 (4.1–8.5) 6.5 (4.8–9.0) 5.0 (3.5–7.4) \ 0.001
Multiple lesions, C 2 162 (17.6) 132 (21.7) 32 (10.2) \ 0.001
Perineural invasion 122 (13.3) 96 (15.8) 26 (8.3) 0.072
Macrovascular invasion 99 (10.8) 71 (11.7) 28 (8.9) \ 0.001
Microvascular invasion 220 (23.9) 164 (27.0) 56 (17.9) 0.172
Direct invasion of adjacent organs 60 (6.5) 54 (8.9) 15 (3.9) \ 0.001
Biliary invasion 113 (12.3) 86 (14.2) 27 (8.6) 0.701
Satellite lesions 191 (20.8) 161 (26.5) 30 (9.6) \ 0.001
AJCC T category \ 0.001
T1–2 703 (76.7) 464 (76.4) 241 (77.0)
T3–4 141 (15.3) 111 (18.3) 30 (9.6)
Missing 74 (8.0) 32 (5.3) 42 (13.4)
Histological grade \ 0.001
Well to moderately differentiated 701 (76.2) 470 (77.4) 231 (73.8)
Poorly to undifferentiated 144 (15.7) 114 (18.8) 30 (9.6)
Missing 75 (8.2) 23 (3.8) 52 (16.6)
Morphologic type 0.059
Mass-forming or papillary 751 (71.6) 485 (79.9) 266 (73.8)
Periductal infiltrating ± mass-forming 169 (18.4) 122 (20.1) 45 (14.4)
Margin (mm) 0.225
\ 1 96 (10.4) 73 (12.0) 23 (7.3)
1–4 325 (35.3) 224 (36.9) 101 (32.3)
5–9 264 (28.7) 163 (26.9) 101 (32.3)
C 10 169 (18.4) 124 (20.4) 45 (14.4)
Lymphadenectomy 407 (44.2) 303 (49.9) 104 (33.2) \ 0.001
Lymph node metastasis 171 (42.0) 132 (43.7) 39 (37.5) 0.009
Major hepatectomy 495 (53.8) 364 (60.0) 131 (41.9) 0.063
Major vascular resection 101 (11.0) 70 (11.5) 31 (9.9) 0.760
Bile duct resection 186 (20.2) 112 (18.5) 74 (23.6) \ 0.001
Intraoperative blood loss (ml) 400 (200–800) 450 (200–800) 300 (200–600) 0.291
Duration of surgery (min) 200 (120–315) 200 (120–310) 177 (96–322) 0.318
Postoperative major complications 124 (13.5) 87 (14.4) 37 (11.8) 0.106
Adjuvant chemo-/radiotherapy 286 (31.1) 231 (38.1) 55 (17.6) \ 0.001
Adjuvant chemotherapy 283 (30.8) 226 (37.2) 57 (18.2) \ 0.001
Adjuvant radiotherapy 46 (5.0) 35 (5.8) 11 (3.5) 0.447
Data are expressed as n(%) unless otherwise specified
IQR interquartile range, BMI body mass index, CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, AJCC American Joint
Committee on Cancer
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recurrence at another location in the liver was identified in
15 patients, 5 of whom also had concomitant extrahepatic
recurrence.
Patients who experienced an intrahepatic margin recur-
rence (median DFS 6.0 months), as well as patients who
recurred with extrahepatic-only recurrence (median DFS
8.9 months) had the shortest DFS (Fig. 1c). In contrast,
patients with intrahepatic recurrence that occurred at a site
other than the original resection margin had the longest
median DFS (14.4 months; p\ 0.001). Of note, within
6 months following curative-intent resection, only 14% of
intrahepatic other site recurrences had occurred compared
with 50.3% of all intrahepatic margin recurrences having
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FIG. 1 a Distribution of recurrence patterns at different time points.
b Recurrence stratified by recurrence patterns at different time points.
c Disease-free survival among patients who experienced different
recurrence patterns. IntraM intrahepatic margin recurrence,
IntraOther intrahepatic other site recurrence, ExtraOnly
extrahepatic-only recurrence, Intra ? Extra intrahepatic plus
extrahepatic recurrence, Recur recurrence, DFS disease-free
survival, CI confidence interval
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extrahepatic-only recurrence and 32.5% of intrahepatic
plus extrahepatic recurrences occurred within the first
6 months following curative-intent resection (Fig. 1b).
Among patients who developed tumor recurrence after
surgery, patients with intrahepatic recurrence in segments
other than the original resection margin had a longer
median OS (51.5 months) compared with patients who
experienced an intrahepatic margin recurrence (median OS
18.8 months; p\ 0.001; electronic supplementary Fig. 1).
Risk Factors Associated with Different Recurrence
Patterns
In assessing the entire cohort on multivariate analysis,
specific tumor characteristics such as lymph node metas-
tasis (HR 1.22, 95% CI 1.13–1.31; p\ 0.001), tumor
size[ 5 cm (HR 1.86, 95% CI 1.39–2.50; p\ 0.001), and
multiple tumors (HR 1.66, 95% CI 1.26–2.19; p\ 0.001)
were associated with an increased risk of tumor recurrence
after curative resection of ICC (electronic supplementary
Table 1). In addition, several factors were associated with
specific patterns of recurrence. For example, surgical
margin\ 10 mm (HR 2.07, 95% CI 1.06–4.04; p = 0.034)
and major hepatectomy (HR 2.05, 95% CI 1.00–4.17;
p = 0.049) were associated with an increased risk of
intrahepatic margin recurrence (Table 2). Patient and liver
factors such as female sex (HR 2.12, 95% CI 1.40–3.22;
p\ 0.001) and liver cirrhosis (HR 2.36, 95% CI 1.31–4.25;
p = 0.004) were both associated with an increased risk of
de novo intrahepatic recurrence away from the surgical
margin (Table 3), while tumor size[ 5 cm (HR 1.82, 95%
CI 1.05–3.15; p = 0.032) was associated with risk of
extrahepatic-only recurrence (electronic supplementary
Table 2).
Survival After Recurrence
Median survival after recurrence was 11.3 months (95%
CI 9.6–12.4) among the 607 patients who recurred. Among
these patients, 485 (79.9%) had detailed information
regarding treatment of the recurrent disease. Perhaps not
surprisingly, median survival after recurrence was better
among the 88 patients who underwent repeat curative-in-
tent surgery versus the 397 patients receiving other
treatments (median survival after recurrence 48.6 vs.
9.7 months; p\ 0.001; Fig. 2). Of note, 289 patients who
received chemotherapy and/or radiotherapy for recurrent
disease had a comparable survival after recurrence com-
pared with the 44 patients who underwent non-curative
surgery. The 49 patients who received intra-arterial therapy
and the 15 patients treated with only best supportive care
had the worst survival after recurrence (Fig. 2).
DISCUSSION
A high incidence of recurrence is one of the major factors
contributing to poor outcome among patients with ICC after
curative-intent surgical resection. Based on a large, inter-
national, multi-institutional database, data from the current
study defined the timing course, survival impact, and risk
factors associated with different patterns of recurrence fol-
lowing resection of ICC. Specifically, half of all recurrences
at the intrahepatic surgical margin site occurred as early as
6 months after surgery. In contrast, approximately only one-
third of extrahepatic-only recurrences and concomitant
intrahepatic and extrahepatic recurrences occurred within
6 months after surgery. Of note, 80% of intrahepatic recur-
rence sites distant from the surgical margin occurred 2 years
after surgery. In addition, specific recurrence patterns had a
different DFS. For example, patients who had a non-surgical
margin intrahepatic recurrence had a better DFS than
patients with other patterns of recurrence. Furthermore, the
risk factors associated with different recurrence patterns
varied, suggesting possible unique biological characteristics
of ICC disease based on the site of recurrence. Perhaps not
surprisingly, attempts at curative-intent re-resection of the
recurrence were associated with better outcomes versus
patients treated with other modalities. Collectively, the data
suggested that different recurrence patterns after surgical
resection for ICC may reflect unique tumor biological
behavior, which may impact choices about surveillance and
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FIG. 2 Survival after recurrence with different treatment options.
OS overall survival
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Isolated intrahepatic recurrence has been reported to be
among the most common sites of recurrence for ICC after
curative-intent surgery.16 In fact, in the current study,
53.2% of all recurrences occurred only within the liver.
Unlike previous studies, we were able to identify distinct
characteristics of intrahepatic margin recurrence versus
intrahepatic other site recurrence. Of note, margin recur-
rence occurred earlier in the postoperative course and was
associated with inadequate/smaller resection margin width.
Inadequate margin has previously been reported as a risk
factor for tumor recurrence after resection of ICC.19,20
Several studies reported that margin width affected long-
TABLE 2 Risk factors of intrahepatic margin recurrence
Variable N = 145 (%) Univariate analysis Multivariate analysis
p value HR (95% CI) p value HR (95% CI)
Age[ 65 years 37 (25.5) 0.102 0.72 (0.48–1.07)
Male sex 75 (51.7) 0.025 0.67 (0.47–0.95) 0.771 0.91 (0.49–1.69)
Liver cirrhosis 24 (16.6) 0.080 1.50 (0.95–2.36)
Tumor size[ 5 cm 102 (70.3) 0.451 1.16 (0.79–1.70)
Nodal metastasis 35 (52.2) 0.047 1.59 (1.01–2.53) 0.097 1.14 (0.98–1.32)
Poorly to undifferentiated 23 (15.9) 0.844 0.95 (0.59–1.54)
Macrovascular invasion 14 (9.7) 0.737 0.90 (0.50–1.64)
Microvascular invasion 39 (26.9) 0.326 1.22 (0.82–1.81)
Multiple tumors 36 (24.8) 0.228 1.28 (0.86–1. 89)
Margin\ 10 mm 84 (57.9) 0.003 1.82 (1.22–2.72) 0.034 2.07 (1.06–4.04)
Adjuvant chemo-/radiotherapy 47 (32.4) 0.009 0.61 (0.42–0.88) 0.140 0.62 (0.33–1.17)
Major hepatectomy 76 (52.4) 0.003 1.65 (1.18–2.29) 0.049 2.05 (1.00–4.17)
Major vascular resection 10 (6.9) 0.857 1.06 (0.56–2.02)
Bile duct resection 21 (14.5) 0.016 1.83 (1.12–2.98) 0.978 1.01 (0.44–2.33)
Periductal infiltrating ± mass-forming 29 (20.0) \ 0.001 1.58 (1.27–1.96) 0.069 2.22 (0.94–5.24)
HR hazard ratio, CI confidence interval
TABLE 3 Risk factors of intrahepatic recurrence at other sites rather than margin
Variable N = 178 (%) Univariate analysis Multivariate analysis
p value HR (95% CI) p value HR (95% CI)
Age[ 65 years 67 (37.6) 0.876 0.97 (0.69–1.37)
Male sex 99 (55.6) 0.022 1.47 (1.05–2.08) \ 0.001 2.12 (1.40–3.22)
Liver cirrhosis 19 (10.7) 0.013 2.02 (1.16–3.50) 0.004 2.36 (1.31–4.25)
Tumor size[ 5 cm 116 (65.2) 0.781 1.05 (0.75–1.48)
Nodal metastasis 25 (29.1) 0.526 1.17 (0.72–1.91)
Poorly to undifferentiated 28 (15.7) 0.815 0.95 (0.60–1.49)
Macrovascular invasion 13 (7.3) 0.361 1.35 (0.71–2.58)
Microvascular invasion 40 (22.5) 0.516 1.14 (0.77–1.67)
Multiple tumors 39 (21.9) 0.136 1.35 (0.91–1. 99)
Margin\ 10 mm 122 (68.5) 0.039 1.62 (1.03–2.56) 0.103 1.62 (1.03–2.56)
Adjuvant chemo-/radio therapy 65 (36.5) 0.205 0.80 (0.57–1.13)
Major hepatectomy 100 (56.2) 0.387 0.88 (0.65–1.18)
Major vascular resection 11 (6.2) 0.982 1.01 (0.55–1.86)
Bile duct resection 26 (14.6) 0.449 0.85 (0.56–1.29)
Periductal infiltrating ± mass-forming 38 (21.3) 0.741 0.94 (0.65–1.36)
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term outcomes, with an incremental worsening of DFS and
OS as margin width decreased.21,22 Although the definition
of R0 resection for ICC remains controversial,4,19,20 the
current study noted that a margin width of\ 10 mm was
associated with intrahepatic margin recurrence. In fact,
inadequate margin could not only be a marker of technical
quality but also a signature of worse disease biology.19–22
In contrast to surgical margin recurrence, recurrences in
the remnant liver at sites other than the margin increased
gradually, with 80% having occurred within 2 years after
surgery. Intrahepatic non-margin recurrence was not asso-
ciated with past surgical technique, rather de novo
intrahepatic recurrence was strongly associated with
patient- and liver-specific factors. In particular, consistent
with previous studies, we noted that non-margin liver
recurrence was associated with the presence of liver cir-
rhosis.4,11, 20, 23 Recurrence as a consequence of underlying
liver cirrhosis most likely represented de novo recurrence,
which was different from the recurrence of the initial
tumors at the surgical margin.16 Of note, among the 22
patients who developed recurrence more than 5 years after
surgery, most (68.2%) had intrahepatic recurrence at sites
other than the surgical margin. Future studies should aim to
define possible genetic and clonal variations in margin
versus non-margin intrahepatic recurrent ICC tumors.
Another important finding of the current study was the
different time courses and DFS among patients with dif-
ferent first site recurrence patterns. Several studies have
noted that most recurrences of ICC occurred during the first
2 years after the initial surgery.24–26 As such, recurrence of
ICC has been divided into early and late stages, using
24 months after surgery as the time cut-off.3,11 In the
current study, when patients were stratified according to
different recurrence patterns, intrahepatic margin recur-
rence was noted to occur earlier than other recurrence
types. In addition, intrahepatic margin recurrence had the
worst DFS, followed by extrahepatic-only recurrence and
both intrahepatic and extrahepatic recurrence. Of note,
patients with non-margin intrahepatic recurrence had the
longest DFS. Close margins (\ 10 mm) were associated
with early margin recurrence with short DFS. In contrast,
extrahepatic-only recurrence was related to initial tumor
characteristics such as tumor size (5 cm), which has been
recognized as a prognostic risk factor in the AJCC
8th edition staging system of ICC.27,28
Management of recurrent ICC remains a clinical chal-
lenge. Repeat curative resection for recurrent ICC has been
associated with improved outcomes compared with adju-
vant chemotherapy or best supportive care.2,8,29 In the
current study, median survival after recurrence was indeed
better among patients who underwent repeat curative-intent
surgery versus other treatments. As such, repeat surgery
can be considered in the small subset of patients with
limited recurrent disease who have good tumor biology.
Unfortunately, most patients with recurrent disease will not
be candidates for repeat resection. These patients with
unresectable recurrent ICC may benefit from systematic
adjuvant chemotherapy.30–32
The current study had several limitations. The retro-
spective study design may have led to inherent selection
bias, given that only patients who underwent a resection
were included in the study. While the multi-institutional
collaboration undoubtedly increased the sample size, there
were likely some discrepancies in patient selection, follow-
up, and adjuvant therapies among the centers. While
surveillance practices of different centers may have varied
somewhat, the majority of patients had regular follow-up as
noted. However, it is likely that a subset of patients who
had suspicious imaging or laboratory findings and under-
went more frequent imaging would be more likely to be
diagnosed with recurrence earlier.
CONCLUSIONS
The current study provided detailed information on
timing, patterns, and risk factors associated with different
recurrence patterns after surgery for ICC. Intrahepatic
margin recurrence was likely to be a recurrence due to
residue tumor at the surgical margin as this pattern of
recurrence was associated with an initial narrow
(\ 10 mm) surgical margin. Surgical margin recurrence
occurred early and was associated with the worse DFS. In
contrast, non-surgical margin intrahepatic recurrence was
more likely to occur later in the natural history of the
patient’s postoperative course. The fact that non-margin
recurrence was associated with underlying liver disease
and took a longer time to develop suggested that this
manifestation of disease was likely de novo disease rather
than ‘true’ recurrence. The different recurrence patterns
and timing of recurrence suggest biological heterogeneity
of ICC tumor recurrence. In turn, understanding the timing
and risk factors associated with the different types of
recurrence can hopefully inform discussions around adju-
vant therapy, surveillance, and treatment of recurrent
disease.
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